Target intelligence / Profile preview

Influenza A virus (H1N1) antigens (H1N1 antigens)

Target: H1N1 antigens
Molecular classification: Viral protein, Glycoprotein, Hemagglutinin, Neuraminidase

Overview

Influenza A virus (H1N1) antigens, primarily hemagglutinin (HA) and neuraminidase (NA), are essential determinants of infectivity and immunity. Their structure includes defined variable regions targeted by neutralizing antibodies. Rapid evolution through drift/shift enables evasion from pre-existing immunity leading to recurring outbreaks. Laboratory preparations provide material for diagnostics/vaccine development but require appropriate biosafety measures due to pathogenicity risks.

Other names: H1N1 HAH1N1 NeuraminidaseH1N1 HemagglutininSwine Flu AntigensInfluenza A/H1N1H1N1 surface glycoproteins

Mechanism of action

Oseltamivir and Zanamivir inhibit neuraminidase activity, preventing the release of new virions. Amantadine and Rimantadine inhibit the M2 protein, preventing viral uncoating. Baloxavir marboxil inhibits the cap-dependent endonuclease, preventing viral RNA replication.

Biological functions

Host cell bindingViral entryViral releaseImmune response elicitationAntigen presentation

Disease associations

Influenza A infectionSeasonal epidemicsPandemicsRespiratory illness

Safety considerations

Antigenic driftAntigenic shiftResistance to antiviral drugsPotential for pandemic emergenceEgg allergy (for egg-derived vaccines)

Interacting drugs

Oseltamivir

4 more in the full profile.

Biomarkers

HA antibody titerNA antibody titerViral loadSeroconversion rate

Beyond the preview

Go deeper on Influenza A virus (H1N1) antigens (H1N1 antigens).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus (H1N1) antigens (H1N1 antigens).

Explore the full profile